Attorney Amy Witherite: Finally Some Common Sense About Driverless Trucks on Texas Highways
DALLAS--(BUSINESS WIRE)--Attorney and traffic safety expert Amy Witherite is glad to see human beings back in the cabs of autonomous trucks on Texas highways. Aurora Innovations reversed course less than three weeks after it said it would let the trucks operate at speeds up to 75 miles an hour between Dallas and Houston without anyone in the cab.
'Common sense has finally prevailed,' said Amy Witherite an attorney and truck safety expert who has been warning about the dangers posed by driverless trucks for months.
'There has been nowhere near the amount of testing required to show these trucks can operate safely in the challenging environment on Texas highways,' said Witherite. 'With billions of dollars at stake and little or no government regulations federal and state officials are letting the fox guard the henhouse by allowing for-profit companies to determine whether their technology is safe.'
Even organizations formed to support the deployment of autonomous vehicles recognize the need for federal standards to be in place. According to the Autonomous Vehicle Industry Association, 'only the federal government can uniformly regulate the design, construction and performance of the vehicle.'
Currently, autonomous vehicles must only follow National Highway Traffic Safety Administration (NHTSA) Federal Motor Vehicle Safety Standards, which were written before automated systems were developed. This creates a regulatory gap between traditional vehicles and newer vehicles equipped with emerging technology.
According to the Washington Post, the 'NHTSA, a small, specialized team focused on autonomous vehicles has lost most of its staff, according to two former agency employees. NHTSA has recently lost many of its employees to Trump administration budget cut.'
'The amount of damage that can be caused by an 80,000-pound tractor trailer far exceeds the severity of accidents involving cars and SUVs,' noted Witherite. 'Texas highways are often crowded and full of complex and unpredictable situations from sudden changes in the weather and ongoing construction to accidents and dangerous drivers.'
'At this point, it took another company PACCAR, Inc. which manufactures the trucks to demand humans remain in the cab of these vehicles,' said Witherite. 'We can only hope that regulators and the public will demand that this commonsense approach continues as this new technology is developed in the future.'
The Witherite Law Group specializes in vehicle accident cases and offers crucial support for individuals involved in accidents with driverless vehicles. For more information visit their website. www.witheritelaw.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Yahoo
11 hours ago
- Yahoo
Americans Call Distracted Driving Dangerous, But Few Admit to Doing It
According to a new Verra Mobility study released for Distracted Driving Awareness Month, 85% of Americans believe distracted driving is just as dangerous as drunk driving. That stat alone should give anyone pause. But here's the kicker: while most drivers say they see reckless behavior on the road all the time, far fewer are willing to admit they've done it themselves. So what did the numbers really show, and what should they mean for everyday drivers like us? Verra Mobility surveyed 2,000 frequent drivers across the U.S. The vast majority say they're noticing bad behavior regularly: 89% say they see speeding at least a few times per week 67% report seeing someone run a red light at least once a month 65% have spotted drivers using their phones while behind the wheel 60% have witnessed someone speeding in a school zone And overall, 63% of respondents believe the average driver has gotten worse in recent years. These observations line up with national data. According to the National Highway Traffic Safety Administration, distracted driving led to more than 3,000 deaths in 2024. That's not just a statistic—it's thousands of families impacted by something as preventable as checking a text message. Here's where things get interesting. When asked about their own driving, people painted a much rosier picture. 65% say they've never driven distracted in the past year 74% claim they haven't used their phone behind the wheel 85% say they've never sped in a school zone It's a bit of a reality check. We may see ourselves as safe and alert, but the numbers suggest we're often not as careful as we think. But here's the disconnect: AAA has found that 87% of U.S. drivers engage in unsafe behaviors behind the wheel. And according to the National Highway Traffic Safety Administration, distracted driving was responsible for more than 3,000 deaths and over 400,000 injuries in 2022 alone. So, while we're pretty quick to notice risky behavior in others (like speeding or phone use), we're not always as honest about our own habits. Despite the disconnect between what people see and what they report doing, one thing is clear: most Americans want safer streets, especially when kids are involved. 59% support automated enforcement to curb dangerous driving 77% support it for school zones A whopping 96% support it for school buses These tech-enabled tools, like speed cameras and red-light enforcement, aren't just about catching bad behavior — they're designed to reduce it. And they're shown to work, especially in school zones and high-risk areas. Jon Baldwin, EVP of Government Solutions at Verra Mobility, summed it up this way: "I believe that the average American is a good driver and cares about safety... being self-aware is key to making our roads safer so that everyone takes responsibility for their own driving behavior." If you're reading this and thinking, 'Yeah, I've seen bad drivers,' maybe it's also a good moment to ask: How often am I fully focused when I'm behind the wheel? The next time your phone buzzes, or a shortcut tempts you to speed through a yellow light, take a beat. Our streets — and the lives on them — deserve your full attention.
